Eton Pharmaceuticals, Inc. ETON · Stock Open Eton Pharmaceuticals, Inc. in new tab
Eton Pharmaceuticals, Inc. Analysis (ETON)
Is Eton Pharmaceuticals, Inc. a good investment? Eton Pharmaceuticals, Inc. (ETON) is currently trading at 55.31 USD. Market analysts have a consensus price target of 71.00 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 140.88. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Eton Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is 2.58.
Investor FAQ
Does Eton Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Eton Pharmaceuticals, Inc.?
Eton Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of 0.40.
Company Profile
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Community Discussion